<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00960453</url>
  </required_header>
  <id_info>
    <org_study_id>SNUCPT09_Sitagliptin</org_study_id>
    <nct_id>NCT00960453</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Investigate the Pharmacokinetics/Pharmacodynamics of Sitagliptin</brief_title>
  <official_title>Multiple-dose, Dose Escalation Study to Investigate the Pharmacokinetics/Pharmacodynamics of Sitagliptin in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the pharmacokinetics and pharmacodynamics of&#xD;
      sitagliptin in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the pharmacokinetics after repeated administrations of sitagliptin 25, 50 and 100 mg</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the pharmacodynamics (activity of Dipeptidyl peptidase-IV enzyme) after repeated administrations of sitagliptin 25, 50 and 100 mg</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48 hours after drug administration</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Sitagliptin 25mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Repeated administrations for 4 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin 50mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Repeated administrations for 4 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin 100mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Repeated administrations for 4 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Dosage form: 25mg, 50mg ,100mg&#xD;
Amount: 25mg, 50mg, 100mg&#xD;
Frequency and duration: once a day, for 4 days, including 5 days washout periods</description>
    <arm_group_label>Sitagliptin 100mg</arm_group_label>
    <arm_group_label>Sitagliptin 25mg</arm_group_label>
    <arm_group_label>Sitagliptin 50mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male subjects aged 20 - 50 years&#xD;
&#xD;
          -  A body mass index (BMI) in the range 17-28 kg/m2&#xD;
&#xD;
          -  Fasting plasma glucose levels in the range 70-110 mg/dL&#xD;
&#xD;
          -  Sufficient ability to understand the nature of the study and any hazards of&#xD;
             participating in it&#xD;
&#xD;
          -  Provide written informed consent after being fully informed about the study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence or history of severe adverse reaction to any drug (e.g., sitagliptin) or a&#xD;
             history of severe allergic disease&#xD;
&#xD;
          -  Clinically relevant abnormal medical history that could interfere with the objectives&#xD;
             of the study&#xD;
&#xD;
          -  A subject who has the following screening laboratory test results; creatinine&#xD;
             clearance (calculated by Cockcroft-Gault equation) &lt; 80 mL/min&#xD;
&#xD;
          -  History of gastrointestinal disease or surgery (except simple appendectomy or repair&#xD;
             of hernia), which can influence the absorption of the study drug&#xD;
&#xD;
          -  A subject whose SBP is over 150 mmHg or below 100 mmHg and DBP is over 95 mmHg or&#xD;
             below 65 mmHg&#xD;
&#xD;
          -  Presence or history of drug abuse&#xD;
&#xD;
          -  Participation in other clinical trial within 2 months&#xD;
&#xD;
          -  Use of a prescription medicine, herbal medicine within 2 weeks or over-the-counter&#xD;
             medication within 1 week before first dose&#xD;
&#xD;
          -  Blood donation during 2 months or apheresis during 1 month before the study&#xD;
&#xD;
          -  Presence or history of alcohol abuse&#xD;
&#xD;
          -  Users of nicotine-containing substances within the previous three months&#xD;
&#xD;
          -  Use of grapefruit juice, alcohol or smoking during restriction period&#xD;
&#xD;
          -  Subject judged not eligible for study participation by investigator&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University College of Medicine and Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trials Center; Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>August 14, 2009</study_first_submitted>
  <study_first_submitted_qc>August 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2009</study_first_posted>
  <last_update_submitted>February 19, 2011</last_update_submitted>
  <last_update_submitted_qc>February 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Kyung-Sang Yu</name_title>
    <organization>Seoul National University Hospital</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

